Testing for PDL1 in all NSCLC (0, 6, 97%), EGFR (21, 83, 95%), and ALK (7, 89, 96%) testing in non-squamous histology also rose across time periods. This evidence concerns the gene EGFR and non-small cell lung carcinoma.